Evidence map›Paper›PMID 31189519›Full record

Trial reportThe lancet. Diabetes & endocrinology2019

Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial.

Vanita R Aroda, Guillermo González-Galvez, Randi Grøn, Natalie Halladin, Martin Haluzík, György Jermendy, Adri Kok, Petra Őrsy, Mohamed Sabbah, Giorgio Sesti and 1 more

Registry-linked trialAbstract readClinical Trial, Phase IIIComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Trial report in The lancet. Diabetes & endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02501161. Cited by 42 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 5 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02501161 phase3completed

A Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus

Ran2016Enrolled1,012Registered outcomes54Posted comparisons2ConditionsDiabetes, Diabetes Mellitus, Type 2Armsinsulin degludec/liraglutide, Insulin glargine
Open the trial in the graph
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 5 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Review
  14. Review
  15. Article
  16. Observational
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 6 countries.

Vanita R ArodaBrigham and Women's Hospital, Boston, MA, USA; MedStar Health Research Institute, Hyattsville, MD, USA. Electronic address: varoda@bwh.harvard.edu.
Guillermo González-GalvezJalisco Institute of Research in Diabetes and Obesity SC, Guadalajara, Jalisco, Mexico.
Randi GrønNovo Nordisk A/S, Søborg, Denmark.
Natalie HalladinNovo Nordisk A/S, Søborg, Denmark.
Martin HaluzíkInstitute for Clinical and Experimental Medicine and Institute of Endocrinology, Prague, Czech Republic.
György JermendyBajcsy-Zsilinszky Hospital, Budapest, Hungary.
Adri KokUnion and Clinton Hospitals in Alberton, Gauteng, South Africa.
Petra ŐrsyNovo Nordisk A/S, Søborg, Denmark.
Mohamed SabbahHadassah University Hospital, Jerusalem, Israel.
Giorgio SestiDepartment of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.
Robert SilverSouthern New Hampshire Diabetes and Endocrinology, Nashua, NH, USA.
Novo Nordisk (Denmark) · DKBajcsy-Zsilinszky Kórház és Rendelőintézet · HUHadassah Academic College · ILInstitute of Clinical and Experimental Medicine · CZMagna Graecia University · ITMedStar Health · USSouthern New Hampshire Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDurability of glycaemic control might reduce disease burden and improve long-term outcomes. DUAL VIII investigated the durability of insulin degludec plus liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) in patients with type 2 diabetes with the use of a visit schedule that mirrored routine clinical practice.

methodsIn this 104-week international, multicentre, open-label, phase 3b randomised controlled trial, insulin-naive patients aged 18 years and older, with HbA

findingsFrom Jan 8, 2016, to Oct 3, 2018, 1345 patients were screened, of which 1012 (75·2%) were eligible and randomly assigned to either IDegLira (n=506) or IGlar U100 (n=506). 484 (96%) of 506 in the IDegLira group and 481 (95%) of 506 in the IGlar U100 group completed the trial. Baseline characteristics were similar and representative of patients eligible for basal insulin intensification (overall mean diabetes duration 10 years; HbA

interpretationIn patients with uncontrolled type 2 diabetes on oral antidiabetic drugs, initial injectable therapy with IDegLira resulted in fewer patients reaching the treatment intensification criterion during 104 weeks versus IGlar U100, with longer durability of the treatment effect with IDegLira.

fundingNovo Nordisk.

Indexed as

AgedDiabetes Mellitus, Type 2Drug CombinationsFemaleHumansHypoglycemic AgentsInsulin GlargineInsulin, Long-ActingLiraglutideMaleMiddle AgedTreatment OutcomeDrug CombinationsHypoglycemic AgentsIDegLiraInsulin GlargineInsulin, Long-ActingLiraglutide

Identifiers

PMID31189519
OpenAlexW2949026862

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.